The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance

The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance

Cyclin-dependent kinases (CDKs) govern cell-cycle checkpoint transitions necessary for cancer cell proliferation. Recent developments have illustrated nuanced important differences between mono CDK inhibitor (CDKI) treatment and the combination therapies of breast cancers. The CDKIs that are current...

Full description

Bibliographic Details
Main Authors:	Mary Abdelmalak, Rajanbir Singh, Mohammed Anwer, Pavel Ivanchenko, Amritdeep Randhawa, Myra Ahmed, Anthony W. Ashton, Yanming Du, Xuanmao Jiao, Richard Pestell
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	Cancers
Subjects:	abemaciclib advanced breast cancer CDK4/6 inhibitor hormone receptor-positive palbociclib ribociclib
Online Access:	https://www.mdpi.com/2072-6694/14/21/5388

Similar Items

Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer
by: Marcin Kubeczko, et al.
Published: (2023-01-01)

CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
by: Hanxiao Xu, et al.
Published: (2017-04-01)

Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases
by: Marcin Kubeczko, et al.
Published: (2023-03-01)

Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania
by: Adina Turcu-Stiolica, et al.
Published: (2024-02-01)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
by: Erin R. Scheidemann, et al.
Published: (2021-11-01)

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
by: A. van Ommen-Nijhof, et al.
Published: (2018-11-01)

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
by: Elisa Agostinetto, et al.
Published: (2023-11-01)

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysis
by: Yiyuan Liu, et al.
Published: (2023-08-01)

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
by: Marina Elena Cazzaniga, et al.
Published: (2023-10-01)

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Vera Martins, et al.
Published: (2023-09-01)

An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer—A Systematic Review of Randomized Phase II and III Clinical Trials
by: Ioana-Miruna Stanciu, et al.
Published: (2023-09-01)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
by: Lu Turković, et al.
Published: (2022-05-01)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
by: Abdel-Razeq H, et al.
Published: (2022-03-01)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01)

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
by: Valentina Rossi, et al.
Published: (2019-10-01)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
by: Francesco Schettini, et al.
Published: (2018-12-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
by: Cui Zhang, et al.
Published: (2024-01-01)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
by: Malek Horani, et al.
Published: (2023-10-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
by: Claudia Omarini, et al.
Published: (2020-05-01)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
by: Naiba Nabieva, et al.
Published: (2023-03-01)

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
by: Cengiz Karacin, et al.
Published: (2023-02-01)

Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells
by: Gregory T. Gallanis, et al.
Published: (2023-03-01)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020-03-01)

Clinical Impact of CDK4/6 Inhibitors in De Novo or PR− or Very Elderly Post-Menopausal ER+/HER2− Advanced Breast Cancers
by: Hiu Tang, et al.
Published: (2023-10-01)

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
by: Eriseld Krasniqi, et al.
Published: (2022-11-01)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
by: Mridula A. George, et al.
Published: (2021-07-01)

CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis
by: Ni Zeng, et al.
Published: (2023-06-01)

The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis
by: Yu-Cheng Chang, et al.
Published: (2023-10-01)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023-03-01)

<i>MYCN</i> Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors’ Efficacy in Neuroblastoma Cells
by: Piergiuseppe De Rosa, et al.
Published: (2023-03-01)

The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
by: Eda Caliskan Yildirim, et al.
Published: (2023-08-01)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
by: Zhimin Zhu, et al.
Published: (2023-07-01)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
by: Ernest H Law, et al.
Published: (2023-04-01)

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
by: Vittorio Gebbia
Published: (2023-04-01)

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
by: Andreas Schneeweiss, et al.
Published: (2020-12-01)

Targeting CDK4/6 for Anticancer Therapy
by: Jiating Qi, et al.
Published: (2022-03-01)

Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy
by: Angel Charles, et al.
Published: (2021-01-01)